YALE NEWS: Study finds no association between COVID-19 vaccines and stillbirths

New Haven, Conn. — In a new study funded by the U.S. Centers for Disease Control and Prevention, researchers from Yale and 11 other institutions found “no association between COVID-19 vaccination and stillbirth.”

In a case-control study led by Yale School of Medicine’s Dr. Anna Denoble, researchers compared 276 stillbirths with 822 live births during a one-year period from February 2021 to February 2022. Their results, published June 6 in the journal Obstetrics & Gynecology, found no linkage between pregnant individuals receiving a COVID-19 vaccine and stillbirth outcomes. 

“Stillbirth is a heartbreaking experience for parents,” said Denoble, assistant professor of obstetrics, gynecology and reproductive sciences and first author of the study. “Expecting parents don’t want to do anything that might harm their pregnancy. We wanted to provide reassurance surrounding COVID-19 vaccine in pregnancy by carefully exploring whether there was any association with stillbirth. We found no association.

Yale’s Dr. Sangini Sheth, an associate professor of obstetrics, gynecology and reproductive sciences was also part of the research team.

While vaccine hesitancy remains a public health challenge, the researchers noted, the results show that “vaccination remains the most effective tool for preventing hospitalizations and morbidity due to COVID-19 and is recommended in pregnancy by the CDC and the American College of Obstetricians and Gynecologists.” 

For the study, the researchers analyzed hundreds of records from the CDC’s Vaccine Safety Datalink [VSD], comparing receipt of the COVID-19 vaccine during pregnancy between those who had stillbirths [defined as fetal death at or beyond 20 weeks of pregnancy] and those who had live births. Each confirmed stillbirth was compared with up to three live births that had similar variables, including maternal age, pregnancy start date, health care site, and exposure to at least one COVID-19 vaccination during pregnancy. There was no significant difference in COVID-19 vaccination between the two groups.

According to their findings, 38.4% of patients experiencing stillbirth received a COVID-19 vaccine in pregnancy compared with 39.3% of those with live births.

The researchers also found “no association … detected by vaccine manufacturer or number of doses received during pregnancy.” Denoble says this is all in line with additional research recently published by the same research team that also showed no difference in other pregnancy outcomes between those who were vaccinated and those who were not. 

Denoble and co-authors say this research “has several strengths and advantages over previous studies” of the same topic. They point out that stillbirth cases were clinically reviewed by obstetrician investigators, “reducing misclassifications.” Also, a larger number of stillbirth cases were included and the use of the VSD provided comprehensive COVID-19 vaccination data, “often not possible in other U.S. studies.”

“The results of this robust case-control study can be used to reassure both pregnant patients and health care professionals that COVID-19 vaccination in pregnancy is not associated with an increased risk of pregnancy loss,” said Denoble. 

END